DOI: https://dx.doi.org/10.18203/2349-2902.isj20214820
Published: 2021-12-28

A case report on asymptomatic and biochemically silent pheochromocytoma in adrenal incidentaloma

Ashiq Ahmed, S. Swetha Priyadharshini, R. Kannan

Abstract


Pheochromocytoma are rare tumours originating from the chromaffin tissue. The clinical manifestations are variable and are not specific as pheochromocytoma and often imitate other diseases. The diagnosis is established by measurement of catecholamines and their metabolites in urine or plasma and by radiographic studies for localisation. Surgical removal of the tumour is the preferred treatment. 45 years old female presented with adrenal incidentaloma of about 6.1×6.2×5.4 cm well defined heterogenous lesion with internal cystic areas seen in right adrenal region abutting upper pole of right kidney. Biochemical investigations for adrenal hormones including plasma aldosterones, cortisols, plasma metanephrines, 24 hrs urinary metanephrines and VMA were found to be normal. Proceeded with adrenelectomy and histopathology of the specimen revealed pheochromocytoma as diagnosis. Pheochromocytoma leads to high mortality and morbidity rates if untreated. Fractionised metanephrines and catecholamines in a 24 hrs urine analysis is the preferred biochemical test. In a biochemically silent pheochromocytoma imaging modalities are used to identify and locate the tumour. Adequete alpha and beta blockade should be ensured before tumour removal. Surgery is recommenced irrespective of size and normal biochemical study to prevent complications.


Keywords


Pheochromocytoma, Adrenal incidentaloma, Urinary metanephrines and catecholamines, Adrenelectomy

Full Text:

PDF

References


Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-34.

Chen YY. Pheochromocytoma presenting with normal urinary catecholamines and metabolites: A case report. Formos J Endocrin Metab. 2009;1(1):33-7.

Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234(2):479-85.

Boraschi P, Braccini G, Grassi L, Campatelli A, Vito A, Mosca F, et al. Incidentally discovered adrenal masses: evaluation with gadolinium enhancement and fat-suppressed MR imaging at 0.5 T. Eur J Radiol. 1997;24(3):245-52.

Blake MA, Krishnamoorthy SK, Boland GW, Sweeney AT, Pitman MB, Harisinghani M, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol. 2003;181(6):1663-8.

Kudva YC, Sawka AM, Young WF. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab. 2003;88(10):4533-9.

Goldstein RE, Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755-64.

Salmenkivi K, Arola J, Voutilainen R, Ilvesmäki V, Haglund C, Kahri AI, et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab. 2001;86(5):2231-5.

Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma. Front Horm Res. 2004;31:45-60.

Young WF. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams textbook of endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; 2008: 505-537.

Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg. 2004;91(10):1259-74.

Grant F. Anesthetic considerations in the multiple endocrine neoplasia syndromes. Curr Opin Anaesthesiol. 2005;18(3):345-52.